The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.
News|Articles|September 2, 2001
- Pharmaceutical Technology-09-02-2001
- Volume 25
- Issue 9
Six Sigma Can Give Contractors a Quality Advantage
Author(s)Jim Miller
This projectbased qualityimprovement program uses shortterm goals to achieve the longterm objectives of constant, continuous improvement.
Advertisement
Articles in this issue
about 25 years ago
Industry Changes OTC Labels as Deadline Approachesabout 25 years ago
A Report of the PQRI Workshop on Blend Uniformityabout 25 years ago
Are You Ready for Global Manufacturing?about 25 years ago
Pharmaceutical Coverage and Costsabout 25 years ago
Outsourcing OutlookAdvertisement
Related to this article
France’s 2030 Health Initiative is driving growth in biotechnology, health innovation, biomanufacturing, and digital health.
argenx will acquire Unnatural Products for up to $1.15B, bringing oral macrocyclic peptides and new formulation challenges to its antibody portfolio.
CDMOs, OEMs, and Used Equipment Resellers are Joining Forces to Onshore Pharmaceutical Manufacturing
Onshoring pharmaceutical manufacturing can be made more practical by collaborating with CDMOs that have gray space, supported by strong relationships with used equipment dealers and OEMs.
Boehringer, AbbVie, ASKA, and Evommune license ADC, IBD, thyroid eye disease, and degrader assets, raising tech transfer demands for manufacturers.
CDMOs announced expansions, exhibitors showcased automated equipment, and supply chain strategy discussions were a focus at CPHI Milan 2026.
Mitigating nitrosamine risk requires assessing each product individually and chasing zero nitrite in pharmaceutical excipients is often impractical and costly.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
2
$1.15B AI-Guided Macrocycle Discovery Lands at argenx
3
Pimicotinib TGCT Approval Shows How Assessment Aid Supports Review
4
Our Biggest Takeaways From AAPS PharmSci 360
5